Osimertinib
- Generic Name
- Osimertinib
- Brand Names
- Tagrisso
- Drug Type
- Small Molecule
- Chemical Formula
- C28H33N7O2
- CAS Number
- 1421373-65-0
- Unique Ingredient Identifier
- 3C06JJ0Z2O
- Background
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and...
- Indication
Osimertinib is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations (as detected by an FDA-approved test), and as the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGF...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
- Associated Therapies
- First Line Chemotherapy
First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting
- Conditions
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 500
- Registration Number
- NCT04391283
- Locations
- 🇨🇳
The First Affiliated Hospital of College of Medicine Zhejiang University, Hangzhou, Zhejiang, China
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 358
- Registration Number
- NCT04351555
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 6000
- Registration Number
- NCT04322890
- Locations
- 🇨🇳
Yongchang Zhang, Changsha, Hunan, China
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04285671
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 57
- Registration Number
- NCT04233021
- Locations
- 🇫🇷
Centre Hospitalier Aix-Pertuis, Aix-en-Provence, France
🇫🇷CHU Amiens - Groupe Hospitalier Sud, Amiens, France
🇫🇷CHU Besançon - Hôpital J. MINJOZ, Besançon, France
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 300
- Registration Number
- NCT04181060
- Locations
- 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2019-11-04
- Target Recruit Count
- 80
- Registration Number
- NCT04148898
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 24
- Registration Number
- NCT04141644
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Collin Blakely
- Target Recruit Count
- 38
- Registration Number
- NCT04085315
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
- Conditions
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 587
- Registration Number
- NCT04035486
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.